Rong  Zhou net worth and biography

Rong Zhou Biography and Net Worth

Rong Zhou, M.S., has served as Executive Vice President of Production Center since June 2015, President of Armstrong Pharmaceuticals since March 2014, President of Amphastar Nanjing Pharmaceuticals since April 2021 (both are Amphastar’s subsidiaries), and as our Senior Vice President of Scientific Affairs since August 2012. Mr. Zhou served as Corporate Vice President of Scientific Affairs from October 2001 until his promotion to Senior Vice President. From July 2000 to October 2001, Mr. Zhou was Vice President of Scientific Affairs of International Medication Systems (Amphastar Pharmaceutical’s subsidiary company). From July 1999 to July 2000, Mr. Zhou was Associate Vice President of Scientific Affairs of Amphastar Pharmaceuticals. From November 1998 to July 2000, Mr. Zhou was Director of Validation Department of International Medication Systems. From 1992 to 1998, Mr. Zhou was a Principle Chemist at Gensia (Sicor) Pharmaceutical’s. Mr. Zhou received a B.S. in Chemical Engineering from the Fuzhou University in 1982 and an M.S. from the Youngstown State University in 1992.

What is Rong Zhou's net worth?

The estimated net worth of Rong Zhou is at least $4.60 million as of December 1st, 2023. Mr. Zhou owns 112,420 shares of Amphastar Pharmaceuticals stock worth more than $4,600,226 as of April 25th. This net worth evaluation does not reflect any other investments that Mr. Zhou may own. Additionally, Mr. Zhou receives a salary of $835,050.00 as EVP at Amphastar Pharmaceuticals. Learn More about Rong Zhou's net worth.

How old is Rong Zhou?

Mr. Zhou is currently 65 years old. There are 4 older executives and no younger executives at Amphastar Pharmaceuticals. The oldest executive at Amphastar Pharmaceuticals is Dr. Yongfeng Zhang Ph.D., Co-Founder, President, CEO, Chief Scientific Officer & Director, who is 77 years old. Learn More on Rong Zhou's age.

What is Rong Zhou's salary?

As the EVP of Amphastar Pharmaceuticals, Inc., Mr. Zhou earns $835,050.00 per year. There are 3 executives that earn more than Mr. Zhou. The highest earning executive at Amphastar Pharmaceuticals is Dr. Yongfeng Zhang Ph.D., Co-Founder, President, CEO, Chief Scientific Officer & Director, who commands a salary of $2,130,000.00 per year. Learn More on Rong Zhou's salary.

How do I contact Rong Zhou?

The corporate mailing address for Mr. Zhou and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on Rong Zhou's contact information.

Has Rong Zhou been buying or selling shares of Amphastar Pharmaceuticals?

Rong Zhou has not been actively trading shares of Amphastar Pharmaceuticals during the last quarter. Most recently, Rong Zhou sold 3,514 shares of the business's stock in a transaction on Monday, December 4th. The shares were sold at an average price of $59.58, for a transaction totalling $209,364.12. Following the completion of the sale, the executive vice president now directly owns 112,420 shares of the company's stock, valued at $6,697,983.60. Learn More on Rong Zhou's trading history.

Who are Amphastar Pharmaceuticals' active insiders?

Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amphastar Pharmaceuticals?

In the last year, insiders at the sold shares 28 times. They sold a total of 514,725 shares worth more than $27,557,288.75. The most recent insider tranaction occured on April, 1st when Director Floyd F Petersen sold 500 shares worth more than $21,715.00. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.

Information on this page was last updated on 4/1/2024.

Rong Zhou Insider Trading History at Amphastar Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2023Sell3,514$59.58$209,364.12112,420View SEC Filing Icon  
12/1/2023Sell4,316$58.58$252,831.28112,420View SEC Filing Icon  
6/15/2023Sell5,000$51.79$258,950.0096,888View SEC Filing Icon  
6/13/2023Sell5,000$48.24$241,200.0088,313View SEC Filing Icon  
5/18/2023Sell10,000$44.20$442,000.0087,598View SEC Filing Icon  
2/8/2022Sell7,000$26.77$187,390.00View SEC Filing Icon  
1/10/2022Sell20,928$25.36$530,734.08View SEC Filing Icon  
11/11/2021Sell7,813$21.67$169,307.71View SEC Filing Icon  
7/26/2021Sell6,000$20.87$125,220.0092,244View SEC Filing Icon  
7/20/2021Sell5,187$20.57$106,696.59View SEC Filing Icon  
6/8/2021Sell8,180$19.34$158,201.20View SEC Filing Icon  
5/13/2021Sell700$19.58$13,706.0096,965View SEC Filing Icon  
6/3/2020Sell13,163$18.82$247,727.66View SEC Filing Icon  
5/6/2019Sell9,600$22.76$218,496.0066,707View SEC Filing Icon  
3/1/2019Sell3,200$25.00$80,000.0055,230View SEC Filing Icon  
2/5/2019Sell4,289$23.00$98,647.0056,319View SEC Filing Icon  
12/3/2018Sell1,089$22.00$23,958.00View SEC Filing Icon  
11/9/2018Sell2,173$20.50$44,546.5054,392View SEC Filing Icon  
12/5/2016Sell61$20.70$1,262.7036,991View SEC Filing Icon  
6/15/2016Sell1,551$15.85$24,583.3537,137View SEC Filing Icon  
12/16/2015Sell772$14.29$11,031.8825,460View SEC Filing Icon  
6/17/2015Sell1,000$16.48$16,480.00View SEC Filing Icon  
See Full Table

Rong Zhou Buying and Selling Activity at Amphastar Pharmaceuticals

This chart shows Rong Zhou's buying and selling at Amphastar Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More

Today's Range

Now: $40.67
Low: $40.39
High: $41.07

50 Day Range

MA: $45.09
Low: $38.65
High: $55.51

2 Week Range

Now: $40.67
Low: $35.62
High: $67.66

Volume

80,237 shs

Average Volume

451,206 shs

Market Capitalization

$1.99 billion

P/E Ratio

15.76

Dividend Yield

N/A

Beta

0.84